Keynote Panel at OSI

Few areas of biotechnology have expanded as rapidly – or attracted as much scientific, commercial, and investor attention – as the treatment of obesity and overweight. Successful partnerships can be critical to advancing innovative therapies in this space, but what are pharma companies and investors really looking for when evaluating opportunities?

With a growing number of our clients working in the obesity field, it has become an increasingly important area of focus for Boston Biodevelopment.

We are pleased to sponsor Obesity Science & Innovation USA 2026 in Boston, MA during Biotech Week, and are excited to announce that our Founder & CEO, Helena Correia, will moderate a keynote panel on September 23rd.

Joined by experts from pharma and leaders in biotech, Helena will lead a conversation exploring the priorities, expectations, and considerations that help shape successful partnerships across the obesity and metabolic disease landscape.